Select Your Location:
Global
France
Italy

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Disease State: Non-Hodgkin lymphoma

Alessandra Tedeschi, Giorgio Minotti, Joe-Elie Salem, Stephan Stilgenbauer

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video
26 May 2025
Clemens Wendtner, Renata Walewska, Pier Luigi Zinzani, Matthew Davids

Overview of the treatment options for treatment naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and the use of BTKis in indolent lymphomas presented at the EHA2024 Hybrid Congress.

Video
26 May 2025